Navigation Links
U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
Date:11/20/2013

BURLINGTON, Mass., Nov. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through examination of U.S. patient-level claims data, total patient share of platform injectable disease-modifying therapies (DMTs) among recently treated multiple sclerosis (MS) patients declined over four quarters of data collection ending June 30, 2013, with a steeper drop observed in Q2 2013, coinciding with the launch of Biogen Idec's Tecfidera. Quarterly analysis shows that injectable DMTs, namely the interferon betas and Teva's Copaxone, captured a combined 70 percent patient share among recently treated patients in Q2 2013 compared with 80 percent one year earlier. Meanwhile, during the drug's first three months on the market, Tecfidera captured a sizable patient share in this population, approaching the level of Novartis's first-to-market oral DMT Gilenya in this same quarter. These data likely reflect both pent up patient demand for Tecfidera and prescribers' positive opinions of the product's clinical profile compared with other DMTs.

However, the Treatment Algorithms in Multiple Sclerosis report also finds that platform injectables continued to capture a commanding 84 percent of first-line patient share among MS DMTs. Copaxone and Biogen Idec's Avonex were most often prescribed among newly diagnosed MS patients, together capturing over 60 percent of first-line patient share in this population, likely owing to their established advantages in tolerability and delivery, respectively. Thanks to physician comfort and a positive long-term safety record, injectable DMTs maintained a dominant first-line position despite the availability of newer oral alternatives—Gilenya, Tecfidera and Genzyme's Aubagio—which combined to capture only just 6 percent of first-line patient share, driven mostly by Gilenya.

"U.S. claims data confirm that time-tested injectables remain a core component of MS treatment, overall and in treatment-naive patients, likely due in part to neurologists' conservative adoption of new agents," said Decision Resources Senior Director Jonathan W. Searles. "That said, with oral DMTs capturing nearly 18 percent total patient share in the second quarter among patients in our sample who were recently treated, and with the use of Tecfidera surging, we anticipate continued steady losses among current mainstays over the near-term."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of ViroPharma, Inc. - VPHM
2. Omnicare (NYSE: OCR) Agrees to Pay United States $120 Million to Settle False Claims Act Suit Alleging Kickbacks
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
4. Gene By Gene Rejects BRCA1/2 Patent Infringement Claims by Myriad and Joins Ambry Genetics to Sue Myriad for Violating Federal Antitrust Laws
5. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG
7. Specialty pharmacy utilization management programs and 30-day supply claims may improve patient outcomes, reduce waste
8. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
9. FDA Publicly Challenged to Support Unsubstantiated Claims Regarding Electronic Cigarettes
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
11. Argus Announces Next Generation Pharmacy Claims Processing Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/7/2017)... 2017 Endo International plc (NASDAQ: ... Hon. Joseph R. Goodwin , U.S. District Court ... Virginia , entered a case management order in ... Products Liability Litigation (the "MDL") that includes a provision ... expert disclosures on specific causation within one hundred twenty ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... 28, 2017 , ... Designers Insurance Agency, a privately owned ... and DC, is announcing a cooperative charity event in conjunction with the Insight ... that lead to memory impairment. , The Insight Memory Care Center (IMCC) offers ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly ... to survey data released today by the American Society for Dermatologic Surgery ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled since ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... solution for many of the health care industry’s hospitals and provider groups, has ... financing portal for select customers. Parasail Health is a San Francisco health-finance startup ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
Breaking Medicine News(10 mins):